50 results about "Streptococcus mastitidis" patented technology

The invention provides engineering lyase Art-15 with broad-spectrum antibacterial activity, antibacterial peptide NZ2114 and bacteriophage lyase PlySs2 are subjected to functional fusion through an optimally designed flexible linker, and an efficient bactericidal effect on Staphylococcus aureus (Staphylococcus aureus) and Streptococcus spp.) is achieved. The engineering lyase Art-15 has the advantages that the engineering lyase Art-15 has broad-spectrum antibacterial activity, the antibacterial peptide NZ2114 and the bacteriophage lyase PlySs2 are subjected to functional fusion through the optimally designed flexible linker, and the engineering lyase Art-15 has broad-spectrum antibacterial activity; the lyase Art-15 overcomes the defects of narrow host spectrum and insufficient splitting activity of the lyase through a synergistic destruction mechanism of targeting bacterial cell wall peptidoglycan. Experiments show that the minimal inhibitory concentration (MIC) of the lyase Art-15 on staphylococcus aureus in vitro is lower than 2 mu g / mL, the minimal inhibitory concentration of the lyase Art-15 on streptococcus agalactiae is lower than 1 mu g / mL, the minimal inhibitory concentration of the lyase Art-15 on streptococcus dysgalactiae is lower than 2 mu g / mL, and the sterilization rate of the lyase Art-15 can reach 97% or above within 30 minutes by 2 times of MIC. The lyase Art-15 disclosed by the invention has important application value in the fields of drug-resistant bacterium infection treatment, medical instrument disinfection and livestock breeding.

The invention relates to the technical field of biology, in particular to a detection method for tilapia streptococcus agalactiae resistance, a KASP primer group and application. According to the invention, the key SNP site of the ABCB4 gene, which is obviously associated with the streptococcus agalactiae disease resistance, of the tilapia is identified by a population genetics method, a typing method of the SNP site is developed by a KASP technology, efficient evaluation on disease resistance characters is realized, experimental data shows that the survival time of an AA genotype individual in a challenge test is prolonged compared with that of a GA / GG genotype individual, and the survival time of the AA genotype individual in the challenge test is obviously prolonged compared with that of a GA / GG genotype individual. The proportion of resistant fishes is remarkably increased, and genotype frequency distribution is strongly related to group disease resistance. According to the breeding strategy based on the SNP marker, the disease resistance of bred groups can be integrally improved, the morbidity and death rate are reduced, an efficient genetic improvement tool is provided for breeding of tilapia mossambica for resisting streptococcus agalactiae diseases, the loss of breeding diseases is reduced, and antibiotic dependence is reduced.

The invention relates to the technical field of biology, in particular to an SNP (Single Nucleotide Polymorphism) marker combination for identifying tilapia streptococcus agalactiae disease resistance and application thereof. The invention discloses 11 SNP loci significantly related to streptococcus agalactiae resistance in a tilapia UTRN gene, and constructs 18 SNP marker combinations for streptococcus agalactiae resistance phenotype identification, so that the resistance phenotype identification accuracy and hereditary stability can be effectively improved. Besides, according to the SNP typing primer and method based on the # imgabs0 # MALDI-TOF mass spectrum platform, high-throughput and high-precision genetic typing can be achieved, and the SNP typing primer and method have important application value in resistance phenotype identification and assistant selective breeding.

The invention relates to the technical field of biology, in particular to a tilapia mossambica streptococcus agalactiae resistance related KASP molecular marker and application thereof. According to the invention, two SNP (Single Nucleotide Polymorphism) loci, namely SNP-1 and SNP-2, which are remarkably associated with resistance are screened based on an intron region of an EGFRX2 gene of tilapia mossambica, a typing method of the loci is developed through a KASP technology, and relevance between the genotype of the SNP-1 and a resistance phenotype is verified. Furthermore, streptococcus agalactiae resistance dominant diplotype individuals are screened in combination with double SNP loci, and the survival rate of a challenge experiment is remarkably improved. The detection kit provided by the invention can realize high-throughput and high-precision typing, is suitable for tilapia mossambica resistance genotype identification and molecular marker-assisted breeding, provides an efficient genetic improvement tool for tilapia mossambica disease-resistant breeding, and is beneficial to reduction of breeding disease loss and reduction of antibiotic dependence.

The application discloses a kind of fluorescence colorimetric double-mode detection streptococcus agalactiae without aerosol pollution method, comprising the following steps: (1) strain culture and DNA extraction;(2) the combination of UDG and LAMP;(3) UDG-LAMP-CRISPR fluorescence mode detection system;(4) colorimetric mode detection system: read image RGB value in G value, G value significantly increases, and it is positive result.This patent innovatively combines UDG, LAMP, CRISPR and G4, introduces connection probe to realize "fluorescence-colorimetric" single system double-mode detection.The two detection modes of the detection platform can be freely split or combined, and can meet the needs of different detection environments.By combining UDG system and LAMP technology, aerosol pollution possibly carried in amplification process is avoided.Connection probe is introduced, CRISPR fluorescence detection is combined with G4 colorimetric detection, a detection system with "fluorescence-colorimetric" two detection modes is established, which is used for quantitative identification and cross verification of streptococcus agalactiae.

The application discloses a bocachito Nat10 antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to a method based on multiomics, a biological big data based on multiomics data of bocachito, screening and identifying an antibacterial peptide precursor gene sequence, and obtaining an amino acid sequence of the bocachito Nat10 antibacterial peptide through translation design, as shown in SEQ ID NO: 3. Through activity simulation prediction and in-vitro experiment verification, the bocachito Nat10 antibacterial peptide shows inhibitory effects on the growth activities of Streptococcus agalactiae, Salmonella enteritidis, Staphylococcus aureus, Vibrio anguillarum and Escherichia coli, especially on Staphylococcus aureus, and shows the best antibacterial effect at a concentration of 2.5 micromoles per liter. The bocachito Nat10 antibacterial peptide can be used for preparing various bactericidal preparations, including bacteriostatic agents, medicines or additives, and has good practical value and social ecological benefits.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention discloses a streptococcus agalactiae attenuated strain, a vaccine and application of the streptococcus agalactiae attenuated strain, and belongs to the technical field of veterinary biological products. The streptococcus agalactiae attenuated strain is obtained by knocking out a marR gene of a streptococcus agalactiae virulent strain HN016; wherein the nucleotide sequence of the marR gene is as shown in SEQ ID NO: 1. After the marR gene of the streptococcus agalactiae virulent strain HN016 is knocked out, the streptococcus agalactiae attenuated strain of which the virulence is remarkably reduced is obtained, and after the streptococcus agalactiae attenuated strain is prepared into the vaccine, the survival rate of aquatic animals infected with streptococcus agalactiae can be remarkably improved, so that the survival rate of the aquatic animals infected with streptococcus agalactiae is improved. The streptococcus agalactiae attenuated strain has a good application prospect in preparation of drugs for preventing and / or treating streptococcus agalactiae infection of aquatic animals.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present application relates to the field of biotechnology, and more particularly to a SNP marker related to the level of anti-streptococcus agalactiae IgM antibody of tilapia and application thereof. The present application screens out QTLs, functional genes and key signal pathways significantly related to the level of anti-streptococcus agalactiae IgM antibody of tilapia by RNA-Seq and BSA-Seq technologies, and further identifies two SNP markers closely related to the level of anti-streptococcus agalactiae IgM antibody of tilapia, thereby providing important genetic targets and tools for molecular marker-assisted breeding of anti-streptococcus agalactiae of tilapia.

The invention belongs to the field of microorganisms, and discloses a bacterial strain having an antagonistic effect on pathogenic bacteria of cow mastitis and application of the bacterial strain, the bacterial strain SUD-8 having the antagonistic effect is paenibacillus polymyxa, and the bacterial strain SUD-8 has the antagonistic effect on the pathogenic bacteria of cow mastitis and application of the bacterial strain SUD-8 to the pathogenic bacteria of cow mastitis. The strain has an antagonistic effect on klebsiella pneumoniae, escherichia coli, staphylococcus aureus, streptococcus uberis and streptococcus dysgalactiae, and the growth speed in the cow dung back-mattress material is high.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The present application relates to the field of microbial technology, in particular to bacillus subtilis BS-1 and its application in water buffalo silage feed, the strain BS-1 of the present application has good bacteriostatic activity on escherichia coli, salmonella and streptococcus uberis, after mixing and fermenting according to a specific proportion with orange peel and cassava residue, the bacteriostatic spectrum of the obtained silage feed is significantly enhanced, which can simultaneously inhibit escherichia coli, campylobacter jejuni, salmonella, streptococcus uberis, staphylococcus aureus and streptococcus agalactiae that cause diarrhea and mastitis. In the feed, after mixing 60%-75% of orange peel and 25%-40% of cassava residue, the crude protein content of the fermentation product is significantly improved, and the fiber content is reduced. Feeding test shows that the feed can significantly improve the milk yield and milk quality of lactating water buffalo, and effectively alleviate diarrhea. The present application provides a safe, efficient and nutritious silage feed with disease prevention function.

The invention discloses a lactobacillus plantarum bacteriostatic agent and application thereof, and relates to the technical field of microbial engineering. According to the lactobacillus plantarum LP2301 provided by the invention, fermentation liquor of the lactobacillus plantarum LP2301 can be used for effectively inhibiting aquatic pathogenic bacteria streptococcus agalactiae, limiting the growth of the streptococcus agalactiae, reducing the use of antibiotics, ensuring food safety and guaranteeing the health of animals and human beings by secreting metabolites such as bacteriostatic proteins and organic acids. Secondly, the invention provides an application of the lactobacillus plantarum bacteriostatic agent, and the lactobacillus plantarum LP2301 is compounded into the bacteriostatic agent; through multi-target cooperation of the cortex phellodendri extract and the rosmarinic acid, the antibacterial efficiency of single probiotics is remarkably optimized; active ingredients of cortex phellodendri directionally destroy a biological membrane barrier of streptococcus agalactiae and disintegrate an adhesion defense system of pathogenic bacteria; rosmarinic acid blocks a bacterial energy metabolism pathway synchronously, so that pathogens lose proliferative power; and exclusive bacteriocin secreted by the LP2301 accurately breaks down a cell membrane structure, so that fatal killing is realized.

The application belongs to the technical field of Chinese herbal medicines, and particularly relates to a Chinese herbal medicine composition for resisting Streptococcus agalactiae, a preparation method and application thereof. Raw materials for preparing the Chinese herbal medicine composition include cortex mali and cumin. The Chinese herbal medicine composition is easy to obtain and simple to prepare, has no chemical residues, is not prone to drug resistance, has significant bacteriostatic activity on Streptococcus agalactiae, and can be applied to the prevention and treatment of Streptococcus agalactiae disease of fish such as tilapia.

The present invention discloses a method for preparing a eukaryotic expression vector of Nile tilapia CD36 protein and its application. The method comprises extracting RNA from Nile tilapia intestinal tissue and synthesizing cDNA; performing PCR amplification on the coding sequence fragment of the Nile tilapia CD36 gene to obtain the Nile tilapia CD36 protein gene; and then constructing a eukaryotic expression vector pEGFP-N1-CD36 of the Nile tilapia CD36 protein. The eukaryotic expression vector of the nucleotide sequence of the Nile tilapia CD36 protein prepared by the present invention can be used to prepare a product that improves the anti-streptococcal immunity of tilapia. The preparation of the product is simple, easy to operate, and low in cost. The present invention enhances the anti-streptococcal ability of tilapia by overexpressing the Nile tilapia CD36 protein in tilapia, thereby increasing the survival rate of tilapia infected with Streptococcus agalactiae by 60%. In addition, overexpressing the Nile tilapia CD36 protein in tilapia can also reduce the Streptococcus agalactiae load in tilapia. Therefore, it can be seen that the technical solution of the present invention can effectively induce cellular immunity in tilapia.

The invention discloses a Basa fish Mob1b antibacterial peptide as well as a coding sequence, application and a preparation method thereof, an antibacterial peptide precursor gene sequence is screened and identified from a Basa fish multi-omics data set based on a multi-omics method and biological big data, and an amino acid sequence of the Basa fish Mob1b antibacterial peptide as shown in SEQ ID NO: 3 is obtained through translation design; activity simulation prediction and in-vitro experiments prove that the Basa fish Mob1b antibacterial peptide has an inhibition effect on growth activity of streptococcus agalactiae, salmonella enteritidis, staphylococcus aureus, vibrio anguillarum and escherichia coli; the compound can be used for preparing various antibacterial agents, especially gram-positive bacteria streptococcus agalactiae, gram-negative escherichia coli staphylococcus aureus and vibrio anguillarum, can show an antibacterial effect when the concentration is 2.5 mu mol / L, can achieve the best antibacterial effect when the concentration is 5 mu mol / L, can be used for preparing various antibacterial agents and the like, and has good practical value and social and ecological benefits.

The invention provides a tilapia mossambica antibacterial peptide OnLEAP-2 and application thereof, an antibacterial peptide named OnLEAP-2 is cloned from tilapia mossambica, and a large number of antibacterial peptides are obtained through prokaryotic expression. The antibacterial peptide has a very good function of resisting streptococcus agalactiae, so that the survival rate of tilapia mossambica is remarkably increased, and pathogens are efficiently removed. The composition is suitable for bacterial disease control of economic fishes such as tilapia.

The present invention relates to molecular biology and aquaculture breeding, specifically to a method for obtaining a PRMT2 gene mutant by knocking out the gene based on CRISPR / Cas9 technology, and establishing an antibacterial strain of tilapia with a PRMT2 knockout. By knocking out this gene, a tilapia strain resistant to Streptococcus agalactiae can be obtained. Infection experiments revealed that tilapia with a PRMT2 knockout gene exhibited enhanced antibacterial activity compared to wild-type tilapia. This invention provides an important model for disease-resistant tilapia breeding and offers gene targets and new research directions for creating more disease-resistant fish strains and varieties.

The present invention relates to compositions and methods for detecting group B streptococcus (GBS, Streptococcus agalactiae) and identifying the most common genes responsible for clindamycin resistant GBS, such as ermB, ermTR, ermT, lsaC and lsaE, by multiplex real-time PCR assays.

The invention discloses a condom added with sophocarpidine hyaluronic acid lubricating liquid and a preparation method of the condom, and belongs to the technical field of condom production. The core of the method is that after matrine is dissolved, the matrine is added into hyaluronic acid lubricating liquid for the condoms, the hyaluronic acid lubricating liquid containing the matrine is prepared through stirring and mixing, the concentration of the matrine in the hyaluronic acid lubricating liquid is 7.7-25.0 mg / g, when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms, and when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms. And preparing the condom added with the sophocarpidine-containing hyaluronic acid lubricating liquid. According to the condom, inflammation generated after vaginal epithelial cells are stimulated by bacterial structural components is improved through matrine, and the common pathogenic bacteria such as staphylococcus aureus, escherichia coli, enterococcus faecalis and streptococcus agalactiae of vaginitis are inhibited in the using process; and the up-regulation level of NF-kB phosphorylation generated after lipopolysaccharide and peptidoglycan stimulate vaginal epithelial cells is relieved.

The present disclosure relates to the field of aptamers. More particularly, the present disclosure relates to aptamers for the specific binding of Group B Streptococcal (GBS) bacteria, such as Streptococcus agalactiae. Additionally, this disclosure relates to methods of using such aptamers in diagnosing, monitoring or treating diseases, disorders or conditions associated with GBS in patients.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to a multiplex fluorescent quantitative PCR primer probe combination for detecting common pathogenic bacteria in vaginal secretion and application of the multiplex fluorescent quantitative PCR primer probe combination, and belongs to the technical field of biology. The primer probe combination provided by the invention contains any one of primer probe groups 1-7. A specific primer probe combination is designed for a cfb gene and a dits gene of streptococcus agalactiae, a sapB2 gene and a cadF gene of campylobacter fetus, a nuc gene of staphylococcus aureus, an hlyA gene of listeria monocytogenes and a ureaplasma ure gene, and a multiplex fluorescent quantitative PCR detection kit and method are established and used for screening common neonatal pathogenic bacteria carried in the birth canal of a puerpera. Seven pathogenic bacteria can be detected at the same time, the specificity is 100%, the sensitivity reaches 85% or above, the minimum detection limit reaches the femtogram level, clinical intervention and early intervention can be fed back in time, and the situation of neonatal infection is avoided.

The application discloses a tilapia Npy antibacterial peptide, a coding sequence, and a use and a preparation method thereof, and relates to the following technical scheme: based on a multi-omics method, an antibacterial peptide precursor gene sequence is screened and recognized from a tilapia multi-omics data set based on biological big data, and then the tilapia Npy antibacterial peptide amino acid sequence is obtained through translation design, as shown in SEQ ID NO: 3; through activity simulation prediction and in-vitro experiment verification, the tilapia Npy antibacterial peptide shows inhibitory activity to gram-positive streptococcus agalactiae, staphylococcus aureus and gram-negative escherichia coli, especially to streptococcus agalactiae and staphylococcus aureus, and shows good antibacterial effect at a low concentration (2.5 μmol / L), and can be used for preparing antibacterial products, including preparation of an antibacterial agent, preparation of a medicine or preparation of an additive, and has good practical value and social ecological benefits.

The present application relates to oligosaccharide composition and its use. The present application particularly relates to the use of oligosaccharide composition in the preparation of products for preventing and / or treating aquaculture diseases caused by Vibrio parahaemolyticus, Vibrio harveyi and Streptococcus agalactiae, wherein the oligosaccharide composition is obtained by degrading polygalacturonan or pectin by a polygalacturonase as shown in SEQ ID No: 1, under the conditions of a polygalacturonase concentration of 0.045 mg / mL to 0.055 mg / mL, a polygalacturonan concentration of 7% to 9%, and a degradation time of 12 hours to 20 hours. The present application also relates to the use of oligosaccharide composition in aquaculture. The oligosaccharide composition of the present application has good bacteriostatic effect and disease prevention and control effect in aquaculture.

The present invention relates to oligosaccharide compositions and uses thereof. The invention particularly relates to application of an oligosaccharide composition in preparation of products for preventing and / or treating aquaculture diseases caused by vibrio parahaemolyticus, vibrio harveyi and streptococcus agalactiae, and the oligosaccharide composition is obtained by degrading polygalacturonic acid or pectin by polygalacturonase shown as SEQ ID No: 1. The degradation conditions are as follows: the concentration of the polygalacturonase is 0.045 mg / mL to 0.055 mg / mL, the concentration of the polygalacturonic acid is 7% to 9%, and the degradation time is 12 hours to 20 hours. The invention also relates to the use of the oligosaccharide composition in aquaculture. The oligosaccharide composition disclosed by the invention has good effects of inhibiting bacteria and preventing and treating aquaculture diseases.

The present invention relates to the development of a microencapsulated vaccine containing inactivated Streptococcus agalactiae, together with the adjuvants beta glucan and mineral oil, to be administered orally to fish together with feed in pelletised form or coated with the vaccine. In addition, the invention relates to the use of this vaccine to immunise fish, more specifically Nile tilapia (Oreochromis niloticus) to activate both innate and adaptive (humoral and cellular) intestinal mucosal immunity and protect tilapia against streptococcosis. Such a vaccine can be applied in intensive fishing production systems, with the aim of reducing fish mortality, reducing the use of antimicrobials and not causing environmental damage, being easy to administer and control, reducing fish handling, and being suitable for immunising large numbers of animals at the same time without stress and at low cost.

The invention belongs to the technical field of gene engineering, and particularly relates to streptococcus agalactiae Mu-20 and a construction method and application thereof. The fish-derived streptococcus agalactiae which is lack of capsular polysaccharide, free of hyaluronidase activity, free of hemolysis and negative in trehalose fermentation is constructed, the strain number is Mu-20, the fish-derived streptococcus agalactiae is preserved in Guangdong Microbial Culture Collection Center on June 13, 2022, and the preservation number is GDMCC No: 62540; the strain does not carry chloramphenicol resistance marker genes, is high in biological safety, has no risk of virulence enhancement, is high in immunogenicity, and can protect immunized fish from resisting invasion of streptococcus agalactiae, and meanwhile, the attenuated live vaccine is easy to culture, simple to use and low in production cost; the strain provided by the invention can be used for preparing attenuated live vaccines for fish streptococcosis, and has extremely high commercial application value.

The invention discloses a multiplex qPCR (quantitative polymerase chain reaction) detection reagent for detecting spinal infection pathogens. The multiplex qPCR detection reagent comprises specific primers and probes for detecting staphylococcus aureus, staphylococcus epidermidis, escherichia coli, mycobacterium tuberculosis, brucella, klebsiella pneumoniae and streptococcus agalactiae; according to the invention, different fluorescently-labeled probes are utilized to add specific primers and probes of multiple pathogens into a reaction system to detect multiple targets at the same time, and the method has the advantages of good specificity, high sensitivity, short detection period, capability of simultaneously detecting multiple pathogens, rapidness, simplicity, convenience and economy; a convenient method is provided for rapid detection of gynecological pathogens, and the kit has important significance in epidemiological research, clinical early molecular diagnosis and the like.